Happy Thanksgiving! Save 50% on Your MarketBeat All Access Subscription.
  •  days
  •  Hours
  •  Minutes
  •  Seconds
×
S&P 500   4,026.12
DOW   34,347.03
QQQ   286.92
Considerations When Rolling Over a 401(k) into a Roth IRA
THE BEST BLACK FRIDAY DEAL YET (Ad)
Saudi viewers angry over apparent ban on World Cup streaming
Walmart shooting claims teen, young woman, father, mother
THE BEST BLACK FRIDAY DEAL YET (Ad)
Cuba's informal market finds new space on growing internet
Best Buy Proves Brick and Mortar is Here to Stay
THE BEST BLACK FRIDAY DEAL YET (Ad)
Bird flu prompts slaughter of 1.8M chickens in Nebraska
US-England World Cup game seen by 19.98M on US television
S&P 500   4,026.12
DOW   34,347.03
QQQ   286.92
Considerations When Rolling Over a 401(k) into a Roth IRA
THE BEST BLACK FRIDAY DEAL YET (Ad)
Saudi viewers angry over apparent ban on World Cup streaming
Walmart shooting claims teen, young woman, father, mother
THE BEST BLACK FRIDAY DEAL YET (Ad)
Cuba's informal market finds new space on growing internet
Best Buy Proves Brick and Mortar is Here to Stay
THE BEST BLACK FRIDAY DEAL YET (Ad)
Bird flu prompts slaughter of 1.8M chickens in Nebraska
US-England World Cup game seen by 19.98M on US television
S&P 500   4,026.12
DOW   34,347.03
QQQ   286.92
Considerations When Rolling Over a 401(k) into a Roth IRA
THE BEST BLACK FRIDAY DEAL YET (Ad)
Saudi viewers angry over apparent ban on World Cup streaming
Walmart shooting claims teen, young woman, father, mother
THE BEST BLACK FRIDAY DEAL YET (Ad)
Cuba's informal market finds new space on growing internet
Best Buy Proves Brick and Mortar is Here to Stay
THE BEST BLACK FRIDAY DEAL YET (Ad)
Bird flu prompts slaughter of 1.8M chickens in Nebraska
US-England World Cup game seen by 19.98M on US television
S&P 500   4,026.12
DOW   34,347.03
QQQ   286.92
Considerations When Rolling Over a 401(k) into a Roth IRA
THE BEST BLACK FRIDAY DEAL YET (Ad)
Saudi viewers angry over apparent ban on World Cup streaming
Walmart shooting claims teen, young woman, father, mother
THE BEST BLACK FRIDAY DEAL YET (Ad)
Cuba's informal market finds new space on growing internet
Best Buy Proves Brick and Mortar is Here to Stay
THE BEST BLACK FRIDAY DEAL YET (Ad)
Bird flu prompts slaughter of 1.8M chickens in Nebraska
US-England World Cup game seen by 19.98M on US television
NASDAQ:VTYX

Ventyx Biosciences - VTYX Stock Forecast, Price & News

$27.50
-0.34 (-1.22%)
(As of 11/25/2022 08:58 PM ET)
Add
Compare
Today's Range
$27.20
$27.92
50-Day Range
$24.16
$36.74
52-Week Range
$9.50
$41.29
Volume
70,500 shs
Average Volume
322,046 shs
Market Capitalization
$1.56 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$49.43

Ventyx Biosciences MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
79.7% Upside
$49.43 Price Target
Short Interest
Healthy
15.09% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.94mentions of Ventyx Biosciences in the last 14 days
Based on 2 Articles This Week
Insider Trading
Selling Shares
$114,430 Sold Last Quarter
Proj. Earnings Growth
Decreasing
From ($2.01) to ($2.65) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.21 out of 5 stars

Medical Sector

369th out of 1,044 stocks

Pharmaceutical Preparations Industry

173rd out of 510 stocks

VTYX stock logo

About Ventyx Biosciences (NASDAQ:VTYX) Stock

Ventyx Biosciences, Inc., a clinical-stage biopharmaceutical company, develops small molecule product candidates to address a range of inflammatory diseases. Its lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for psoriasis, psoriatic arthritis, and Crohn's disease. It is also developing VTX002, a sphingosine 1 phosphate receptor modulator that is in Phase II clinical trials for the treatment of ulcerative colitis; and VTX2735, a peripheral-targeted NOD-like receptor protein 3 inflammasome inhibitor to treat patients with cryopyrin-associated periodic syndrome. In addition, the company is developing VTX3232, a CNS-penetrant NLRP3 inhibitor. Ventyx Biosciences, Inc. was incorporated in 2018 and is based in Encinitas, California.

Receive VTYX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Ventyx Biosciences and its competitors with MarketBeat's FREE daily newsletter.

VTYX Stock News Headlines

Morgan Stanley Begins Coverage on Ventyx Biosciences (NASDAQ:VTYX)
6 Analysts Have This to Say About Ventyx Biosciences
Ventyx Biosciences Recent Insider Activity
Earnings Outlook For Ventyx Biosciences
Ventyx Biosciences, Inc. (VTYX)
Ventyx Biosciences: Not Chasing This Rally
Why Is Ventyx Biosciences (VTYX) Stock Up 70% Today?
4 Analysts Have This to Say About Ventyx Biosciences
See More Headlines
Receive VTYX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Ventyx Biosciences and its competitors with MarketBeat's FREE daily newsletter.

VTYX Company Calendar

Last Earnings
11/03/2022
Today
11/28/2022
Fiscal Year End
12/31/2022
Next Earnings (Estimated)
3/22/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:VTYX
Fax
N/A
Employees
27
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$49.43
High Stock Price Forecast
$65.00
Low Stock Price Forecast
$35.00
Forecasted Upside/Downside
+79.7%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
7 Analysts

Profitability

Net Income
$-83,750,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$5.55 per share

Miscellaneous

Free Float
28,828,000
Market Cap
$1.56 billion
Optionable
Not Optionable
Beta
N/A

Key Executives

  • Dr. Sheila K. Gujrathi M.D. (Age 52)
    Exec. Chair
    Comp: $81.14k
  • Dr. Raju S. Mohan Ph.D. (Age 64)
    Founder, CEO & Director
    Comp: $783.73k
  • Dr. John M. Nuss Ph.D. (Age 63)
    Chief Scientific Officer
    Comp: $5.57M
  • Mr. Christopher W. Krueger J.D. (Age 54)
    MBA, Chief Bus. Officer
    Comp: $568.14k
  • Prof. William J. Sandborn M.D.
    Ph.D., Pres & Chief Medical Officer
  • Dr. Martin Douglas Auster M.D. (Age 47)
    Chief Financial Officer













VTYX Stock - Frequently Asked Questions

Should I buy or sell Ventyx Biosciences stock right now?

7 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Ventyx Biosciences in the last twelve months. There are currently 7 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" VTYX shares.
View VTYX analyst ratings
or view top-rated stocks.

What is Ventyx Biosciences' stock price forecast for 2023?

7 Wall Street analysts have issued 1-year price objectives for Ventyx Biosciences' stock. Their VTYX share price forecasts range from $35.00 to $65.00. On average, they anticipate the company's share price to reach $49.43 in the next twelve months. This suggests a possible upside of 79.7% from the stock's current price.
View analysts price targets for VTYX
or view top-rated stocks among Wall Street analysts.

How have VTYX shares performed in 2022?

Ventyx Biosciences' stock was trading at $19.86 on January 1st, 2022. Since then, VTYX shares have increased by 38.5% and is now trading at $27.50.
View the best growth stocks for 2022 here
.

When is Ventyx Biosciences' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, March 22nd 2023.
View our VTYX earnings forecast
.

How were Ventyx Biosciences' earnings last quarter?

Ventyx Biosciences, Inc. (NASDAQ:VTYX) released its quarterly earnings data on Thursday, November, 3rd. The company reported ($0.59) EPS for the quarter, missing analysts' consensus estimates of ($0.45) by $0.14.

When did Ventyx Biosciences IPO?

(VTYX) raised $152 million in an IPO on Thursday, October 21st 2021. The company issued 9,472,656 shares at a price of $15.00-$17.00 per share.

What is Ventyx Biosciences' stock symbol?

Ventyx Biosciences trades on the NASDAQ under the ticker symbol "VTYX."

Who are Ventyx Biosciences' major shareholders?

Ventyx Biosciences' stock is owned by many different institutional and retail investors. Top institutional investors include Lord Abbett & CO. LLC (3.07%), Darwin Global Management Ltd. (2.47%), Logos Global Management LP (2.47%), BlackRock Inc. (2.44%), Vivo Capital LLC (2.39%) and Vanguard Group Inc. (1.95%). Insiders that own company stock include Global Strategic Fund I Venbio and Somu Subramaniam.
View institutional ownership trends
.

How do I buy shares of Ventyx Biosciences?

Shares of VTYX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Ventyx Biosciences' stock price today?

One share of VTYX stock can currently be purchased for approximately $27.50.

How much money does Ventyx Biosciences make?

Ventyx Biosciences (NASDAQ:VTYX) has a market capitalization of $1.56 billion.

How can I contact Ventyx Biosciences?

The official website for the company is www.ventyxbio.com. The company can be reached via phone at 760-593-4832 or via email at ir@ventyxbio.com.

This page (NASDAQ:VTYX) was last updated on 11/28/2022 by MarketBeat.com Staff